The $20M milestone payment confirms clinical progress in the Takeda partnership, but the $5M buyback is trivial relative to market cap. Traders should focus on upcoming elritercept data readouts and rinvatercept trial milestones as the next catalysts. Cash runway into H2 2028 reduces near-term dilution risk.
Drugs in focus
KROS drug pipeline →rinvatercept
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 9 $11.31entry
- T+1 · 2mo ago −1.24%α −0.64% · $11.17
- T+5 · 2mo ago −2.39%α −2.05% · $11.04
- T+20 · 6w ago −0.88%α −3.08% · $11.21
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Keros Therapeutics announced a $5 million share repurchase authorization following a $20 million development milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed). The company had $257.6 million in cash as of June 30, 2026, and expects cash runway into the second half of 2028. The modest buyback signals capital return but is not transformative given the clinical-stage status and limited program progress.
Key Facts
- $5 million share repurchase authorized
- $20 million milestone payment from Takeda for elritercept (ELRiSE MDS trial first patient dosed)
- Cash and cash equivalents of $257.6 million as of June 30, 2026
- Cash runway expected into second half of 2028 after milestone and buyback
Financial Impact
$5M buyback vs $221M market cap (~2.3%); $20M milestone adds to existing $257.6M cash; net cash impact ~+$15M
Risk Factors
- Clinical trial failure or delay (elritercept, rinvatercept)
- Pre-revenue stage with no approved products
- Buyback may be modified, suspended, or discontinued at any time
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000053 |
| Exhibit: exhibit9919826pr.htm | 0001664710-26-000053 |
| Document: 0001664710-26-000053-index-headers.html | 0001664710-26-000053 |
| Document: 0001664710-26-000053-index.html | 0001664710-26-000053 |
| Document: 0001664710-26-000053.txt | 0001664710-26-000053 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers